Orlistat and Saxenda both have weight-management contexts in U.S. prescribing information, but they are different types of medicine. Orlistat limits absorption of some dietary fat through intestinal lipase inhibition and is supplied as OTC 60 mg or prescription 120 mg capsules. Saxenda contains liraglutide, a GLP-1 receptor agonist, and has been marketed as a prescription daily injection for eligible weight-management populations. Their mechanisms, labeled age groups, monitoring and adverse effects require separate review.
This comparison has an important time-sensitive feature: Novo Nordisk has announced that it will discontinue the Saxenda brand, with its final wholesale shipments scheduled for late January 2027. The manufacturer says the decision is commercial and not due to a newly identified safety or quality problem. This announcement concerns branded Saxenda supply; it does not establish that every liraglutide product will disappear. FDA records also document a generic injection approved referencing Saxenda in August 2025. The exact marketed product and local availability still require verification.
OrliLab is an independent informational website supported in part by disclosed affiliate referrals. We do not sell Saxenda or orlistat, provide prescriptions, guarantee inventory or recommend abrupt treatment changes. Readers considering continued Saxenda treatment or a possible product transition should discuss timing and available alternatives with their clinician and pharmacist.
This comparison is a weight-management brand decision, unlike comparisons involving diabetes-branded Victoza. The distinction between an oral, meal-related lipase inhibitor and a prescribed GLP-1 daily injection remains important even when the discussion also concerns brand supply.
The table includes the announced market transition, which an undated list of weight-loss medicines might omit.
| Dimension | Orlistat | Saxenda |
|---|---|---|
| Ingredient | Orlistat | Liraglutide |
| Mechanism | Gastrointestinal lipase inhibition | GLP-1 receptor agonism |
| U.S. labeled context | Weight management, label-specific eligibility | Weight management in eligible populations |
| Route | Oral capsules | Daily subcutaneous injection |
| Access | 60 mg OTC; 120 mg Rx | Prescription only |
| Current special issue | Identify strength and appropriate label | Branded wholesale shipments planned to end late January 2027 |
Novo Nordisk’s U.S. notice states that its final Saxenda shipments to wholesalers are scheduled for late January 2027. As of October 2026, this remains a future wholesale-supply change, not evidence that the brand has disappeared from every pharmacy. The company attributes the decision to its portfolio strategy and declining use, not to a new safety or quality issue.
The announcement is not described as a safety-related recall. A patient should not infer that a Saxenda prescription becomes invalid on the shipment date, nor assume uninterrupted supply afterward. Saxenda availability and prescription access covers the specific stock-confirmation workflow.
The FDA approved Teva’s generic liraglutide injection referencing Saxenda on August 27, 2025; Teva announced the U.S. launch the following day. This weight-management generic is distinct from generic liraglutide products that reference the diabetes brand Victoza. The Saxenda brand discontinuation therefore does not mean that the liraglutide ingredient has lost all approved U.S. weight-management products.
When discussing transition options, ask the prescriber and pharmacist which reference product, intended indication and actual marketed presentation applies. The liraglutide access overview addresses product-specific prescription verification.
Saxenda has obesity or weight-management labeling for eligible adults and for certain adolescents ages 12–17 with obesity and body weight above 60 kg. Prescription Xenical has a different label, while nonprescription Alli is intended for qualifying adults aged 18 and older. These age and indication distinctions matter when reviewing a possible alternative after the announced Saxenda phaseout.
For families or adults evaluating treatment, a clinician should confirm the particular indication, required evaluation and whether an alternative is appropriate for the patient’s age and health history.
Orlistat product instructions tie administration to meals containing fat. Diet composition can affect both the intended drug action and common gastrointestinal complaints. A clinician may also discuss vitamin supplementation and other medication separation questions.
Saxenda is a daily injected product with prescription titration and injection-handling instructions. Training, tolerability, keeping to prescribed procedures and continued monitoring all differ from buying an OTC capsule. Neither regimen should be inferred from a generic internet comparison.
Orlistat and Saxenda have distinct clinical trial programs for weight management, and published results may involve different baseline risks, lifestyle interventions, follow-up lengths and ways of reporting discontinuation. A headline claim that one drug is a set number of times more effective based on unrelated trials would be misleading.
The orlistat clinical effectiveness overview discusses its evidence. A clinician can review Saxenda-specific trials and more recent alternatives if the patient needs a treatment strategy that can continue after the brand phaseout.
Orlistat commonly causes fatty stools and urgency and may reduce absorption of fat-soluble vitamins. Its labeling includes contraindications and warnings about medication interactions, liver events and rare oxalate-related kidney problems.
Saxenda carries a boxed warning about thyroid C-cell tumors observed in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. It also has warnings including pancreatitis, gallbladder disease and serious gastrointestinal reactions. Orlistat contraindications provides the more detailed orlistat context.
Saxenda is obesity-branded liraglutide; Victoza is diabetes-branded liraglutide. Their dosing frameworks, labeling and commercial status should not be merged. The Saxenda discontinuation announcement cannot be used to claim that Victoza or all liraglutide generics are being discontinued.
For the diabetes-specific question, use orlistat versus Victoza. The product-level boundary keeps this page focused on obesity treatment and supply changes.
Prescription coverage and pharmacy quotes can differ by actual drug, insurer, prior authorization requirements and product supply. A retail catalogue that continues to display Saxenda is not necessarily confirming available stock, particularly near a planned end of wholesale shipments.
Compare actual authorized products rather than assuming a generic has the same final price or availability. Orlistat cost factors are explained separately without fabricated live prices.
For someone already prescribed Saxenda, treatment continuity is a more important question than which headline offers the lowest online price. Discuss remaining supply, refill timing, appropriate continuation and clinically suitable alternatives before stock issues arise.
For orlistat, legitimate buying options follow different OTC and prescription requirements. Neither an online advert nor this comparison establishes whether switching medications is safe or indicated.
Yes. Novo Nordisk announced that the last branded Saxenda shipments to U.S. wholesalers are scheduled for late January 2027. That date concerns wholesale supply, not the expiration of every existing prescription.
No such nationwide live-stock conclusion follows from the announcement. Check the particular pharmacy for current availability.
The manufacturer states the planned brand discontinuation is a portfolio decision and not due to safety or quality concerns.
Yes. The FDA approved Teva’s Saxenda-referencing liraglutide injection in August 2025, and Teva announced a U.S. launch. Pharmacy inventory and the exact product still require confirmation.
No. Both contain liraglutide, but Saxenda is a weight-management brand and Victoza is diabetes-branded. A generic referencing one cannot automatically be treated as the other.
Do not change a prescribed treatment plan without the clinician considering the indication, safety and treatment continuity.
No. Orlistat is supplied as oral capsules; Saxenda is administered by injection.
No. Orlistat has fat-related gastrointestinal and vitamin issues; Saxenda has GLP-1-specific boxed warnings and other precautions.
No. FDA approval establishes a regulatory status; supply depends on the manufacturer, wholesalers, dispensing pharmacy and the requested package. Ask the pharmacy what it can actually dispense.
Discuss the planned end of Saxenda wholesale shipments with the prescriber early, confirm remaining pharmacy stock and ask about clinically appropriate options. Do not switch formulations or medicines without medical guidance.